Target Exclusivity. During the Option Period, MTI shall collaborate exclusively with Licensee with respect to each Designated Target Antigen until such time as [***] or until [***], whichever is earlier. If, however, [***], MTI shall continue to collaborate exclusively with Licensee with respect to such Designated Target Antigen (then deemed an Exclusive Target Antigen) for the remainder of the Term, unless earlier terminated pursuant to Article 13. For purposes of this Section 2.4.7, “collaborate exclusively” means that MTI shall not, [***].
Appears in 2 contracts
Sources: Research Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.), Research Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.)